NMN/NR Mechanism of Action: The Full NAD+ Biosynthesis Pathway Explained

Why NAD+ Matters Before We Discuss Its Precursors

Nicotinamide adenine dinucleotide (NAD+) functions as a coenzyme in over 500 enzymatic reactions, serving as the central electron carrier in glycolysis, the TCA cycle, and oxidative phosphorylation. Without adequate NAD+, cellular energy production stalls. But NAD+ is not just a metabolic shuttle. It acts as a consumed substrate for signaling enzymes (sirtuins, PARPs, and CD38) that regulate DNA repair, epigenetic remodeling, and inflammatory tone 1.

Tissue NAD+ concentrations fall significantly with age. Camacho-Pereira et al. demonstrated that CD38 expression rises in aging tissues, accelerating NAD+ degradation and producing a roughly 50% decline in NAD+ across multiple organs by middle age 2. This age-dependent depletion compromises sirtuin activity, PARP-mediated DNA repair capacity, and mitochondrial function simultaneously. The therapeutic rationale behind NMN and NR supplementation is straightforward: replenish the substrate so the downstream enzymes can function.

"NAD+ is not merely a redox cofactor. It is a rate-limiting substrate for an entire class of signaling enzymes whose activity declines in lockstep with NAD+ availability," as stated in a 2018 review by Yoshino, Baur, and Imai in Cell Metabolism 1.

The Three NAD+ Biosynthesis Pathways

NAD+ can be synthesized through three distinct routes: the de novo pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide. NMN and NR operate exclusively through the salvage pathway, which generates over 85% of total NAD+ in most mammalian tissues 3.

The salvage pathway works in two steps. First, the enzyme nicotinamide phosphoribosyltransferase (NAMPT) converts nicotinamide (NAM) to NMN by attaching a phosphoribosyl group. NAMPT is rate-limiting. Its expression declines in aged tissues, making the first step progressively slower 1. Second, nicotinamide mononucleotide adenylyltransferases (NMNATs 1-3) convert NMN into NAD+ by adding an adenylyl group. Three NMNAT isoforms exist: NMNAT1 in the nucleus, NMNAT2 in the cytoplasm and Golgi, and NMNAT3 in mitochondria. Each services its own subcellular NAD+ pool 3.

Supplemental NMN enters the pathway at the second step, effectively bypassing the rate-limiting NAMPT reaction. NR requires one additional phosphorylation by nicotinamide riboside kinases (NRK1/NRK2) to become NMN before NMNAT can act on it 4. This difference shapes the metabolic kinetics of each precursor, though both converge on the same NMN-to-NAD+ conversion step.

How NMN Enters Cells: The Slc12a8 Transporter

For years, researchers debated whether NMN could cross cell membranes intact or required extracellular dephosphorylation to NR first. That question was largely resolved in 2019 when Grozio et al. identified Slc12a8 as a specific NMN transporter expressed in the small intestine and other tissues 5. Slc12a8 is a sodium-dependent transporter that moves intact NMN across the plasma membrane. Its expression increases when intracellular NAD+ levels drop, creating a feedback mechanism that upregulates NMN import during deficiency states.

This does not mean dephosphorylation is irrelevant. CD73, a 5'-ectonucleotidase on cell surfaces, can convert extracellular NMN to NR, which then enters via equilibrative nucleoside transporters (ENTs) and gets rephosphorylated intracellularly by NRK1/NRK2 4. Both routes operate in parallel. The relative contribution of each likely varies by tissue type and NAD+ status.

Oral NMN bioavailability studies in humans show rapid absorption. A pharmacokinetic trial by Irie et al. found that a single 250 mg oral NMN dose elevated plasma NMN levels within 5 minutes and increased blood NAD+ metabolites by 2 hours 6.

How NR Enters Cells: NRK1/NRK2 Phosphorylation

NR crosses cell membranes through equilibrative nucleoside transporters (ENTs), the same family that handles adenosine and other nucleosides. Once inside the cell, NR must be phosphorylated to NMN by nicotinamide riboside kinases. NRK1 is ubiquitously expressed; NRK2 shows higher expression in skeletal muscle, heart, and brain 4.

The NRK step adds a metabolic gate that NMN bypasses. Whether this difference is clinically meaningful remains debated. Trammell et al. showed that a single 1,000 mg oral dose of NR raised blood NAD+ levels by approximately 2.7-fold within 8 hours in healthy volunteers 7. A comparable NMN dose has not been tested head-to-head in the same trial design, so direct potency comparisons remain speculative.

One practical consideration: NR is less chemically stable than NMN and degrades more readily at room temperature and in acidic environments. Some fraction of orally ingested NR may be cleaved to nicotinamide before absorption, which then enters the salvage pathway at the NAMPT step rather than the NRK step 3. This degradation reduces the effective dose that reaches cells as intact NR.

Downstream Target 1: Sirtuins (SIRT1-7)

Sirtuins are NAD+-dependent deacylases and ADP-ribosyltransferases. They consume one molecule of NAD+ for every acetyl group they remove from a protein substrate, producing nicotinamide and O-acetyl-ADP-ribose as byproducts 8. The nicotinamide generated feeds back into the salvage pathway, but the NAD+ molecule is destroyed in the process. This means sirtuins are not catalytic with respect to NAD+. They are consumers.

Seven mammalian sirtuins occupy distinct subcellular compartments. SIRT1 and SIRT6 in the nucleus regulate gene expression and DNA repair. SIRT2 in the cytoplasm deacetylates tubulin and metabolic enzymes. SIRT3, SIRT4, and SIRT5 reside in mitochondria, governing fatty acid oxidation, the urea cycle, and reactive oxygen species management 8. SIRT7 operates in the nucleolus, regulating ribosomal DNA transcription.

SIRT1 receives the most attention in NAD+ precursor research. It deacetylates PGC-1alpha, the master regulator of mitochondrial biogenesis, and also deacetylates FOXO transcription factors that control antioxidant gene expression and autophagy 1. When NAD+ levels fall below the Km of SIRT1 (approximately 150 to 200 micromolar, depending on the substrate), sirtuin activity drops and mitochondrial quality control suffers. NMN supplementation in aged mice restored tissue NAD+ above this threshold and reversed age-associated mitochondrial dysfunction, as demonstrated by Gomes et al. in Cell 9.

Downstream Target 2: PARPs and DNA Repair

Poly(ADP-ribose) polymerases, particularly PARP1, are the largest consumers of cellular NAD+. PARP1 detects single-strand DNA breaks and synthesizes poly(ADP-ribose) chains on histones and repair proteins, recruiting the base excision repair machinery. Each ADP-ribose unit added costs one NAD+ molecule, and PARP1 can build chains exceeding 200 units at a single damage site 10.

Under genotoxic stress, PARP1 hyperactivation can deplete the entire cellular NAD+ pool within minutes. This creates a vicious cycle: DNA damage activates PARP1, which consumes NAD+, which reduces sirtuin activity, which impairs mitochondrial function, which increases oxidative stress, which causes more DNA damage 1.

NMN and NR supplementation may buffer this depletion cycle by maintaining NAD+ at levels sufficient to support both PARP-mediated repair and sirtuin-mediated mitochondrial maintenance. Mouchiroud et al. showed that boosting NAD+ with NR improved mitochondrial function through a SIRT1-dependent pathway in worms and mice, and that this benefit depended on adequate NAD+ to sustain concurrent PARP activity 11.

Downstream Target 3: CD38 and the Aging NAD+ Sink

CD38 is an ectoenzyme (with its catalytic domain facing outside the cell) and also localizes to intracellular membranes. It degrades NAD+ to cyclic ADP-ribose, ADP-ribose, and nicotinamide. Unlike sirtuins and PARPs, CD38 activity increases with age. Camacho-Pereira et al. demonstrated that CD38 is the primary driver of age-related NAD+ decline in mice, and that CD38 knockout mice maintained youthful NAD+ levels into old age 2.

CD38 expression rises in response to chronic, low-grade inflammation (sometimes called "inflammaging"). Senescent cells and activated macrophages secrete cytokines (IL-6, TNF-alpha) that upregulate CD38 on neighboring cells, creating a tissue-wide NAD+ drain 2. This is a critical concept: NAD+ decline with age is not simply a supply problem. Demand increases simultaneously as CD38 expression climbs.

This dual problem means that NAD+ precursor supplementation faces a moving target. If CD38-mediated degradation outpaces the rate at which NMN or NR can replenish NAD+, the net benefit diminishes. Some researchers are investigating CD38 inhibitors (such as apigenin and 78c) as adjuncts to NAD+ precursor therapy, though human trial data for this combination strategy do not yet exist 2.

The Yoshino 2021 Trial: NMN and Insulin Sensitivity

The most frequently cited human NMN trial is Yoshino et al. (2021), published in Science. This randomized, placebo-controlled, double-blind study enrolled 25 postmenopausal women with prediabetes and administered 250 mg NMN daily for 10 weeks 12.

The primary finding: NMN increased skeletal muscle insulin sensitivity by approximately 25%, measured by hyperinsulinemic-euglycemic clamp (the gold standard for insulin sensitivity assessment). Skeletal muscle showed increased phosphorylation of AKT and mTOR pathway components, along with gene expression changes consistent with enhanced insulin signaling. Muscle NAD+ metabolite levels (specifically NMN and NAD+ measured via mass spectrometry) increased in the treatment group.

"NMN supplementation upregulated the expression of genes involved in muscle remodeling, specifically platelet-derived growth factor signaling pathways," the investigators reported 12.

The sample size was small (N=25). There was no change in body weight, blood pressure, or HbA1c. The effect was tissue-specific, appearing in skeletal muscle but not in adipose tissue insulin sensitivity or hepatic glucose production. Larger, longer trials are needed before insulin-sensitizing effects can be considered established.

NMN vs. NR: Mechanistic Differences That May Matter

Both NMN and NR converge on the same salvage pathway, but their differences in transport, phosphorylation requirements, and chemical stability may produce distinct tissue-specific effects. NMN can enter gut epithelial cells directly via Slc12a8 without prior conversion 5. NR requires NRK-mediated phosphorylation after cellular entry 4.

NR has a longer track record of published human pharmacokinetic data. Martens et al. conducted a crossover trial of NR 1,000 mg/day for 6 weeks in 24 healthy middle-aged and older adults, showing a 60% increase in blood NAD+ with reductions in systolic blood pressure (by 2.1 mmHg on average) and aortic stiffness 13.

NMN human data are accumulating. Yi et al. demonstrated that 12 weeks of NMN at 600 mg or 1,200 mg/day improved aerobic capacity (measured by 6-minute walk distance) in healthy older adults (N=66), with the 600 mg group showing the strongest response 14.

Neither compound has completed a Phase III trial. No head-to-head NMN vs. NR study exists in humans. Choosing between them based on current evidence requires acknowledging substantial uncertainty.

Intracellular NAD+ Compartmentalization

A detail often missed in popular coverage: NAD+ is not a single homogeneous pool. Cells maintain separate NAD+ concentrations in the cytoplasm, nucleus, and mitochondria, and these pools are not freely exchangeable 3. Nuclear NAD+ is maintained primarily by NMNAT1 and supports PARP and sirtuin activity related to gene regulation and DNA repair. Mitochondrial NAD+, maintained by NMNAT3, supports the TCA cycle and oxidative phosphorylation. Cytoplasmic NAD+, maintained by NMNAT2, services glycolysis and cytoplasmic sirtuin (SIRT2) activity.

Whether orally administered NMN or NR preferentially replenishes one compartment over another is poorly characterized in humans. Mouse studies suggest that NMN supplementation increases both nuclear and mitochondrial NAD+ pools, but the kinetics differ 9. This compartmentalization means that total tissue NAD+ measurements may obscure functionally important redistribution between pools.

Safety Profile and Metabolic Fate

NMN doses up to 1,250 mg/day for 4 weeks were well tolerated in a Japanese safety study, with no serious adverse events and no clinically significant changes in laboratory values 6. NR at 1,000 mg twice daily for 24 weeks showed a similarly clean safety profile in the NIAGEN trial, with mild flushing and gastrointestinal symptoms as the most common complaints 13.

The nicotinamide generated as a byproduct of sirtuin and PARP reactions can inhibit sirtuin activity at high concentrations (Ki ~50 micromolar for SIRT1). This creates a theoretical ceiling effect: if NAD+ precursor dosing generates excessive nicotinamide, sirtuin inhibition could partially offset the benefit of higher NAD+ 8. Methylation of nicotinamide to N-methyl-nicotinamide (by NNMT) consumes methyl groups from S-adenosylmethionine, raising theoretical concerns about methyl donor depletion at very high doses. No human study has documented clinically meaningful methyl group depletion from NAD+ precursor supplementation at standard doses.

Patients taking NMN or NR should have baseline and follow-up monitoring of liver function tests and complete blood counts, per the general guidance for high-dose supplement use. No specific drug interactions have been identified in published trials, but concurrent use with PARP inhibitors (used in oncology) has not been studied and should be discussed with a prescribing physician given the shared NAD+ substrate dependency.